Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M K Hagan"'
Publikováno v:
The Journal of Immunology. 152:943-955
IL-6 is a multifunctional cytokine that functions as an autocrine growth factor for AIDS-derived Kaposi's sarcoma (KS) cells. We report that IL-6 is highly inducible at both the mRNA and protein levels in cultured KS cells by multiple agents, yet the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75ba312f707d9f01cb89d90bf68c0c45
https://doi.org/10.4049/jimmunol.152.2.943
https://doi.org/10.4049/jimmunol.152.2.943
Publikováno v:
The Journal of Immunology. 152:361-373
Kaposi's sarcoma (KS) is a neoplasm with multifocal vascular lesions that is often seen in homosexual HIV-infected individuals. Infiltrates of leukocytes are characteristic components of KS lesions, and the products of leukocytes have been shown to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbaa45335e73c4ec1066f9c16ef355af
https://doi.org/10.4049/jimmunol.152.1.361
https://doi.org/10.4049/jimmunol.152.1.361
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 152(2)
IL-6 is a multifunctional cytokine that functions as an autocrine growth factor for AIDS-derived Kaposi's sarcoma (KS) cells. We report that IL-6 is highly inducible at both the mRNA and protein levels in cultured KS cells by multiple agents, yet the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::befeb62a2f8f239c1d8b6197ea58228c
https://pubmed.ncbi.nlm.nih.gov/8283061
https://pubmed.ncbi.nlm.nih.gov/8283061
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 152(1)
Kaposi's sarcoma (KS) is a neoplasm with multifocal vascular lesions that is often seen in homosexual HIV-infected individuals. Infiltrates of leukocytes are characteristic components of KS lesions, and the products of leukocytes have been shown to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::deb1868b53a649223767e1144cc4ca22
https://pubmed.ncbi.nlm.nih.gov/7504714
https://pubmed.ncbi.nlm.nih.gov/7504714
Autor:
Abenaa M. Brewster, Francisco J. Esteva, Sandra X. Franco, K. Koch, William V. Williams, M. Ridderheim, Alejandra T. Perez, A. Florance, M. K. Hagan, Stuart J. Turner
Publikováno v:
Journal of Clinical Oncology. 28:1046-1046
1046 Background: Although concomitant trastuzumab and paclitaxel is an established treatment for metastatic breast cancer (MBC), 30% to 40% of HER2-positive patients show no response to this combination. Lapatinib, with a differing mechanism of actio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::807219750fe11dedbed121131dbaa563
https://doi.org/10.1200/jco.2010.28.15_suppl.1046
https://doi.org/10.1200/jco.2010.28.15_suppl.1046
Autor:
Alejandra T. Perez, S. Franco, Stuart J. Turner, S. Stein, Robert A. Somer, Francisco J. Esteva, M. K. Hagan, C. Dombroski, A. Florance
Publikováno v:
Cancer Research. 69:5085-5085
Background: Trastuzumab given concomitantly with paclitaxel is an established first-line metastatic breast cancer (MBC) treatment; however, approximately 30% to 40% of patients show no response as defined by RECIST to this combination. Lapatinib is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8f4fa6a14ca06f522788e1ac88baf70
https://doi.org/10.1158/0008-5472.sabcs-09-5085
https://doi.org/10.1158/0008-5472.sabcs-09-5085